title: Selegiline diminishes cardiovascular autonomic responses in Parkinson's disease.
abstract: Selegiline (L-deprenyl), a selective inhibitor of monoamine oxidase type B, is an established adjuvant to levodopa therapy in Parkinson's disease (PD). To evaluate whether selegiline also effects the severity and progression of autonomic nervous system dysfunction in PD, we studied autonomic functions by measuring cardiovascular responses to normal breathing, deep breathing, the Valsalva maneuver, the tilting test, and the isometric contraction test prospectively in 52 PD patients receiving either selegiline (n = 27) or placebo (n = 25) in randomized order in a double-blind parallel trial. The study also continued double-blind after the introduction of levodopa. Recordings of cardiovascular responses were carried out annually, with the median follow-up period being 6 years. Cardiovascular autonomic reflexes were diminished in the patient groups compared with those of healthy control subjects (n = 45). There was no progression (except age-related) in dysautonomia in patients on placebo, but there was a decrease in cardiovascular responses in the selegiline group. The heart rate variability in normal breathing, in the Valsalva maneuver, and in the tilting test was clearly diminished during the selegiline treatment. In addition, in the tilting test, the fall in diastolic blood pressure immediately after tilting and in systolic blood pressure 2 minutes after standing up was more pronounced in the selegiline group than in the placebo group. Levodopa treatment had no effect on the measured autonomic responses. In the isometric contraction test, the two treatment groups showed no difference. We conclude that selegiline treatment diminishes autonomic responses, especially those of the sympathetic division. This sympatholytic effect may signal an increased risk of orthostatic hypotension.
authors.affiliation: Department of Neurology, University of Oulu, Finland.
authors.forename: J
authors.initials: J
authors.lastname: Turkka
authors.forename: K
authors.initials: K
authors.lastname: Suominen
authors.forename: U
authors.initials: U
authors.lastname: Tolonen
authors.forename: K
authors.initials: K
authors.lastname: Sotaniemi
authors.forename: V V
authors.initials: VV
authors.lastname: Myllylä
mesh_terms: D000704:Analysis of Variance; D001342:Autonomic Nervous System Diseases / Q000209:etiology / Q000517:prevention & control; D001794:Blood Pressure / Q000187:drug effects*; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D004562:Electrocardiography; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000150:complications*; D011446:Prospective Studies; D012018:Reflex / Q000187:drug effects; D012642:Selegiline / Q000494:pharmacology / Q000627:therapeutic use*; D018667:Tilt-Table Test
chemical_list: D008996:Monoamine Oxidase Inhibitors; D012642:Selegiline; D007980:Levodopa